Our Latest News

January 12, 2021:

DIACCURATE ACQUIRES BIOKINESIS TO CREATE A SOLE-IN-CLASS BIOTECH PLAYER IN ONCOLOGY AND IMMUNOTHERAPY

 

  • BIOKINESIS absorption by DIACCURATE occurred early December 2020

  • Dr. Dominique BRIDON leads the new entity

  • DIACCURATE is now developing 3 programs in cancer and immunotherapy

  • DIACCURATE will be initiating a first clinical trial by early

March 3, 2020

WORLD PREMIERE:

DIACCURATE REVEALS THE MECHANISM OF IMMUNE DISABLEMENT IN HIV INFECTION

L'info dans les médias français

usine nouvelle.png

Paris, France, 24 June 2019

DIACCURATE APPOINTS 4 WORLD-CLASS EXPERTS  
TO HEAD ITS SCIENTIFIC BOARD